Oh Tak Kyu, Song In-Ae, Jeon Young-Tae
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Korea.
Korean J Anesthesiol. 2024 Dec;77(6):614-622. doi: 10.4097/kja.24443. Epub 2024 Oct 14.
We aimed to determine whether propofol-based total intravenous anesthesia (TIVA) is associated with mortality and morbidity following cranial neurosurgery compared with inhalation anesthesia.
This nationwide, retrospective, population-based cohort study included patients who underwent cranial neurosurgery under general anesthesia between January 1, 2016, and December 31, 2021. The two study endpoints were 90-day mortality and postoperative complications.
In total, 144,506 adult patients were included: 65,442 patients (45.3%) who received TIVA (TIVA group) and 79,064 (54.7%) who received inhalation anesthesia (inhalation anesthesia group). After propensity score (PS) matching, 97,156 patients (48,578 in each group) were included. The 90-day mortality rates after cranial neurosurgery were 14.0% (6,660/48,578) in the TIVA group and 14.2% (6,779/48,578) in the inhalation anesthesia group. Moreover, the postoperative complication rates following cranial neurosurgery were 47.1% (22,411/48,578) and 50.3% (23,912/48,578) in the TIVA and inhalation anesthesia groups, respectively. Based on the logistic regression analysis, TIVA was not associated with 90-day mortality compared with inhalation anesthesia (odds ratio [OR]: 0.97, 95% CI [0.94, 1.01], P = 0.188) in the PS-matched cohort. Logistic regression analysis revealed that the TIVA group had a 12% (OR: 0.88, 95% CI [0.86, 0.90], P < 0.001) lower postoperative complication rate than the inhalation anesthesia group.
There was no significant association between the type of anesthesia and postoperative 90-day mortality in patients who underwent cranial neurosurgery in South Korea. However, propofol-based TIVA was associated with a lower incidence of postoperative complications than inhalation anesthesia.
我们旨在确定与吸入麻醉相比,丙泊酚全凭静脉麻醉(TIVA)是否与颅脑神经外科手术后的死亡率和发病率相关。
这项全国性、回顾性、基于人群的队列研究纳入了2016年1月1日至2021年12月31日期间在全身麻醉下接受颅脑神经外科手术的患者。两个研究终点是90天死亡率和术后并发症。
总共纳入了144,506名成年患者:65,442名患者(45.3%)接受了TIVA(TIVA组),79,064名(54.7%)接受了吸入麻醉(吸入麻醉组)。在倾向评分(PS)匹配后,纳入了97,156名患者(每组48,578名)。颅脑神经外科手术后90天死亡率在TIVA组为14.0%(6,660/48,578),在吸入麻醉组为14.2%(6,779/48,578)。此外,颅脑神经外科手术后的并发症发生率在TIVA组和吸入麻醉组分别为47.1%(22,411/48,578)和50.3%(23,912/48,578)。基于逻辑回归分析,在PS匹配队列中,与吸入麻醉相比,TIVA与90天死亡率无关(优势比[OR]:0.97,95%置信区间[0.94, 1.01],P = 0.188)。逻辑回归分析显示,TIVA组的术后并发症发生率比吸入麻醉组低12%(OR:0.88,95%置信区间[0.86, 0.90],P < 0.001)。
在韩国接受颅脑神经外科手术的患者中,麻醉类型与术后90天死亡率之间没有显著关联。然而,丙泊酚TIVA与吸入麻醉相比,术后并发症发生率较低。